Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparing Diabetes Medications

Comparing Diabetes Medications Opinion VIEWPOINT Where Do We Set the Bar? More than 25 million Americans have type 2 diabetes subjects to combination therapy with metformin and 1 Kasia J. Lipska, MD, MHS mellitus and face decisions about which medications to of 4 agents: glimepiride, sitagliptin phosphate, liraglu- Section of use to lower glucose levels. These decisions are increas- tide, or insulin glargine. The primary end point will be the Endocrinology, ingly complex (now involving 12 different classes of glu- time to glucose control failure, defined as a hemoglo- Department of Internal cose-lowering agents) and increasingly costly (result- bin A (HbA ) level of 7% or higher after having been Medicine, Yale School 1c 1c of Medicine, New ing in over $18 billion in annual expenditures ). Yet, treated with metformin and started on therapy with the Haven, Connecticut. despite the enormous health and economic implica- second randomly assigned medication. Although other tions of these decisions, there are few comparative ef- potentially important aspects of the 4-drug combina- Harlan M. Krumholz, fectiveness outcomes studies to guide clinical practice. tions will be assessed (including adverse effects such as MD, SM The major goals of glycemic control in type 2 diabetes weight gain and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Comparing Diabetes Medications

JAMA Internal Medicine , Volume 174 (3) – Mar 1, 2014

Loading next page...
 
/lp/american-medical-association/comparing-diabetes-medications-Z6dT5Ylm3u
Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2013.13433
pmid
24366351
Publisher site
See Article on Publisher Site

Abstract

Opinion VIEWPOINT Where Do We Set the Bar? More than 25 million Americans have type 2 diabetes subjects to combination therapy with metformin and 1 Kasia J. Lipska, MD, MHS mellitus and face decisions about which medications to of 4 agents: glimepiride, sitagliptin phosphate, liraglu- Section of use to lower glucose levels. These decisions are increas- tide, or insulin glargine. The primary end point will be the Endocrinology, ingly complex (now involving 12 different classes of glu- time to glucose control failure, defined as a hemoglo- Department of Internal cose-lowering agents) and increasingly costly (result- bin A (HbA ) level of 7% or higher after having been Medicine, Yale School 1c 1c of Medicine, New ing in over $18 billion in annual expenditures ). Yet, treated with metformin and started on therapy with the Haven, Connecticut. despite the enormous health and economic implica- second randomly assigned medication. Although other tions of these decisions, there are few comparative ef- potentially important aspects of the 4-drug combina- Harlan M. Krumholz, fectiveness outcomes studies to guide clinical practice. tions will be assessed (including adverse effects such as MD, SM The major goals of glycemic control in type 2 diabetes weight gain and

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Mar 1, 2014

References